Studies Support Early Use of ULT, Warn of PAD Studies Support Early Use of ULT, Warn of PAD
A new analysis suggests that it may not be necessary to delay urate-lowering therapy in gout flares, and a study warns of the potential heightened risk for peripheral arterial disease in gout.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2023 Category: Consumer Health News Tags: Rheumatology Source Type: news
Adverse Events Compared for Gout Flare Prophylactic Drugs Adverse Events Compared for Gout Flare Prophylactic Drugs
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no prophylaxis, but these events are rare overall.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 6, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 -- Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open.
Osama Hamid, M.B.B.S., from the Cleveland Clinic, and colleagues investigated the association... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2023 Category: Pharmaceuticals Source Type: news
Colchicine Still Needed in Allopurinol Up-Titration Strategy Colchicine Still Needed in Allopurinol Up-Titration Strategy
Patients taking colchicine had fewer gout flares than did those taking placebo for the first 6 months, but the number of flares evened out between the two groups over a 12-month period.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 11, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
What Changed FDA's Mind About Ilaris for Gout?
(MedPage Today) -- The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 5, 2023 Category: Primary Care Source Type: news
Diabetes Drug Class Appears to Reduce Recurrent Gout Flares Diabetes Drug Class Appears to Reduce Recurrent Gout Flares
Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also appear to reduce gout flare recurrence and excess mortality.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 31, 2023 Category: Endocrinology Tags: Rheumatology News Source Type: news
FDA Approves Canakinumab for Gout Flares FDA Approves Canakinumab for Gout Flares
Canakinumab is first biologic in the US approved for treating gout flares.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 31, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
FTC Attempts To Block Major Biotech Company Merger
In yet another action that would quash medical innovation, Biden administration appointees are trying to block a corporate merger that would allow drugs developed to treat rare but debilitating eye and gout diseases to reach many more patients. The Federal Trade Commission (FTC) has sued in…#ftc #amgen #horizontherapeutics #ireland #amgenhorizon #horizon #tepezza #krystexxa #fda #defenseproductionact (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2023 Category: Consumer Health News Source Type: news
Case Grows for SGLT2 Inhibitors as Gout Treatment
(MedPage Today) -- Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.
Among nearly... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2023 Category: Cardiology Source Type: news
Gout: Suboptimal Management a Continuing Problem Gout: Suboptimal Management a Continuing Problem
Although urate-lowering drugs form the cornerstone of gout therapy, there are only three oral medications currently available in the United States, and all have significant limitations.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 9, 2023 Category: Internal Medicine Tags: Family Medicine/Primary Care Source Type: news
Body Mass Index Affects Risk for Rheumatic Disease
FRIDAY, Aug. 4, 2023 -- Higher body mass index (BMI) increases the risk for rheumatic disease and is a stronger risk factor for psoriatic arthropathy and gout in women, according to a study recently published in Arthritis& Rheumatology.
Torgny... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2023 Category: Pharmaceuticals Source Type: news
Africa: Not Enough Evidence That Ginger Could Effectively Treat Gout - Speak to Your Doctor Instead
[Africa Check] IN SHORT: Ginger has been widely studied for its potential health benefits, including for inflammatory conditions. There is some promising evidence, but not enough to conclude that it can treat gout. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 2, 2023 Category: African Health Tags: Africa Health and Medicine Source Type: news
Young man diagnosed with gout at the age of 18 - 'I’ve never experienced pain like it'
Matt Myles-Brown first recognised something wasn't right after playing a game of football. (Source: Daily Express - Health)
Source: Daily Express - Health - July 30, 2023 Category: Consumer Health News Source Type: news
Saxenda Shortage; New ADA Guidance; Cheap Test for Osteoporosis Risk?
(MedPage Today) -- The shortage of weight-loss drugs now extends to liraglutide (Saxenda). (Fierce Pharma)
Compared with DPP-4 inhibitors, SGLT2 inhibitors helped reduce recurrent gout flare-ups and hospitalizations in people with type 2 diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 25, 2023 Category: Endocrinology Source Type: news
SGLT2i Use Linked to Reduced Risk for Flare in Adults With Gout, T2D
MONDAY, July 24, 2023 -- For patients with gout and type 2 diabetes, sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for recurrent gout flares and gout-primary emergency department visits and hospitalizations,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2023 Category: Pharmaceuticals Source Type: news
